Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents

Design, synthesis and biological screening

Sharad Kumar Suthar, Varun Jaiswal, Sandeep Lohan, Sumit Bansal, Anil Chaudhary, Amit Tiwari, Angel Treasa Alex, Alex Joseph

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Nuclear factor-kappaB (NF-κB) has been reported to regulate various genes involved in cancer and inflammation. Accordingly, drugs suppressing or inhibiting NF-κB may possess both anti-inflammatory and anticancer properties. A library of quinolone substituted thiazolidin-4-ones was docked into the active site of NF-κB and the top-ranked 31 compounds were synthesized and evaluated for anti-inflammatory and anticancer activity. The best-ranked compound 6b showed highest anti-inflammatory activity in carrageenan-induced paw edema model. In vitro anticancer studies revealed 1a and 16a as most active compounds against BT-549, HeLa, COLO-205 and ACHN human cancer cell lines. Compounds 1a and 16a exhibited NF-κB dependent anticancer properties and apoptosis mediated cell death. In vivo Ehrlich ascites carcinoma study further confirmed the antitumor activity of 1a and 16a.

Original languageEnglish
Pages (from-to)589-602
Number of pages14
JournalEuropean Journal of Medicinal Chemistry
Volume63
DOIs
Publication statusPublished - 2013

Fingerprint

Quinolones
Antineoplastic Agents
Screening
Anti-Inflammatory Agents
Carrageenan
Cell death
Ascites
Edema
Catalytic Domain
Neoplasms
Cell Death
Genes
Cells
Apoptosis
Inflammation
Carcinoma
Cell Line
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Suthar, Sharad Kumar ; Jaiswal, Varun ; Lohan, Sandeep ; Bansal, Sumit ; Chaudhary, Anil ; Tiwari, Amit ; Alex, Angel Treasa ; Joseph, Alex. / Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents : Design, synthesis and biological screening. In: European Journal of Medicinal Chemistry. 2013 ; Vol. 63. pp. 589-602.
@article{ea5f3e8269934fa69082324f189aa3af,
title = "Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design, synthesis and biological screening",
abstract = "Nuclear factor-kappaB (NF-κB) has been reported to regulate various genes involved in cancer and inflammation. Accordingly, drugs suppressing or inhibiting NF-κB may possess both anti-inflammatory and anticancer properties. A library of quinolone substituted thiazolidin-4-ones was docked into the active site of NF-κB and the top-ranked 31 compounds were synthesized and evaluated for anti-inflammatory and anticancer activity. The best-ranked compound 6b showed highest anti-inflammatory activity in carrageenan-induced paw edema model. In vitro anticancer studies revealed 1a and 16a as most active compounds against BT-549, HeLa, COLO-205 and ACHN human cancer cell lines. Compounds 1a and 16a exhibited NF-κB dependent anticancer properties and apoptosis mediated cell death. In vivo Ehrlich ascites carcinoma study further confirmed the antitumor activity of 1a and 16a.",
author = "Suthar, {Sharad Kumar} and Varun Jaiswal and Sandeep Lohan and Sumit Bansal and Anil Chaudhary and Amit Tiwari and Alex, {Angel Treasa} and Alex Joseph",
year = "2013",
doi = "10.1016/j.ejmech.2013.03.011",
language = "English",
volume = "63",
pages = "589--602",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents : Design, synthesis and biological screening. / Suthar, Sharad Kumar; Jaiswal, Varun; Lohan, Sandeep; Bansal, Sumit; Chaudhary, Anil; Tiwari, Amit; Alex, Angel Treasa; Joseph, Alex.

In: European Journal of Medicinal Chemistry, Vol. 63, 2013, p. 589-602.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents

T2 - Design, synthesis and biological screening

AU - Suthar, Sharad Kumar

AU - Jaiswal, Varun

AU - Lohan, Sandeep

AU - Bansal, Sumit

AU - Chaudhary, Anil

AU - Tiwari, Amit

AU - Alex, Angel Treasa

AU - Joseph, Alex

PY - 2013

Y1 - 2013

N2 - Nuclear factor-kappaB (NF-κB) has been reported to regulate various genes involved in cancer and inflammation. Accordingly, drugs suppressing or inhibiting NF-κB may possess both anti-inflammatory and anticancer properties. A library of quinolone substituted thiazolidin-4-ones was docked into the active site of NF-κB and the top-ranked 31 compounds were synthesized and evaluated for anti-inflammatory and anticancer activity. The best-ranked compound 6b showed highest anti-inflammatory activity in carrageenan-induced paw edema model. In vitro anticancer studies revealed 1a and 16a as most active compounds against BT-549, HeLa, COLO-205 and ACHN human cancer cell lines. Compounds 1a and 16a exhibited NF-κB dependent anticancer properties and apoptosis mediated cell death. In vivo Ehrlich ascites carcinoma study further confirmed the antitumor activity of 1a and 16a.

AB - Nuclear factor-kappaB (NF-κB) has been reported to regulate various genes involved in cancer and inflammation. Accordingly, drugs suppressing or inhibiting NF-κB may possess both anti-inflammatory and anticancer properties. A library of quinolone substituted thiazolidin-4-ones was docked into the active site of NF-κB and the top-ranked 31 compounds were synthesized and evaluated for anti-inflammatory and anticancer activity. The best-ranked compound 6b showed highest anti-inflammatory activity in carrageenan-induced paw edema model. In vitro anticancer studies revealed 1a and 16a as most active compounds against BT-549, HeLa, COLO-205 and ACHN human cancer cell lines. Compounds 1a and 16a exhibited NF-κB dependent anticancer properties and apoptosis mediated cell death. In vivo Ehrlich ascites carcinoma study further confirmed the antitumor activity of 1a and 16a.

UR - http://www.scopus.com/inward/record.url?scp=84875384373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875384373&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2013.03.011

DO - 10.1016/j.ejmech.2013.03.011

M3 - Article

VL - 63

SP - 589

EP - 602

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -